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Abstract
Diagnostic testing is a crucial aspect of the
clinical decision making, especially in emer-
gency settings where timely and accurate diag-
noses are essential for appropriate patient
management. Reliable statistics attest that the
vast majority of clinical decisions for diagno-
sis, treatment and follow-up of both acute and
chronic diseases are influenced by results of
laboratory analyses. As specifically concerns
the emergency department, many unnecessary
laboratory tests are also ordered in this health-
care setting, with unfavorable consequences
on laboratory and healthcare organization. As
far as the laboratory environment is con-
cerned, defensive (emergency medicine) may
be associated with incremental costs, derange-
ment of laboratory organization, enhanced
complexity of data management process, diag-
nostic delay attributable to performance of
unnecessary testing, and litigation. Educative
or even regulatory interventions are hence
urgently needed to addresses problems of the
current liability system, in order to decrease
the detrimental effects of defensive (emer-
gency) medicine in the laboratory.
Introduction
Diagnostic testing is a crucial aspect of the
clinical decision-making. Reliable statistics
attest that up to 70% of the clinical decisions
for diagnosis, treatment and follow-up of both
acute and chronic diseases are influenced by
results of laboratory analyses, especially in
emergency settings where timely and accurate
diagnoses are essential for appropriate patient
management. This categorical evidence poses
a huge pressure on modern clinical laborato-
ries, since these are forced to face a constant
increase of type and volume of tests. Two inde-
pendent surveys based in the USA and Italy
recently showed that urgent testing represents
a major part of the laboratory workflow,
accounting for as many as 50% of all tests per-
formed in clinical laboratories.1,2 In another
study carried out in 36 different Spanish hos-
pitals, Salinas and colleagues3 also showed
that the rate of stat tests request was highly
heterogeneous, ranging from 44 to 412 per
1000 emergency department (ED) patient
admissions. 
Due to the need of reporting urgent diag-
nostic information to clinicians and emer-
gency physicians, stat analyses need to follow
specific pathways within the laboratory, name-
ly characterized by a shorter turnaround time
compared to conventional testing. This obvi-
ously carries substantial organizational and
economical consequences. Due to their pecu-
liar characteristics, stat analyses have been for
long performed using separate instrumenta-
tion, thus requiring dedicated personnel and
incremental costs for purchasing specific ana-
lyzers and reagents. However, due to the grow-
ing diffusion of automation in clinical labora-
tories, the workflow of urgent testing has
remarkably changed in the past decade, lead-
ing the way to two paradoxically opposite orga-
nizational solutions.4 In some laboratories
urgent testing has now been consolidated
within the so-called corelabs, i.e., aggregation
of many analytical platforms performing differ-
ent types of analyses and physically connected
by belts or other sample conveyors, in which
both stat and routine specimens can be loaded
simultaneously, giving priority to those test
requiring urgent notification. In other facili-
ties, urgent testing has been instead decen-
tralized in peripheral wards, namely EDs and
intensive care units (Figure 1). Both solutions
have advantages and limitations. Despite sel-
dom plagued by a longer turnaround time, the
former approach is indeed more economically
attractive. Conversely, the use of point of care
(POC) instrumentation in clinical wards
allows a rapid release of test results, but obvi-
ously necessitates more expansive POC ana-
lyzers and reagents to be placed at the site of
testing, along with an appropriate education of
both nurses and physicians to run and ensure
quality management of this peculiar type of
analyses. Regardless of the way stat testing is
performed, urgent testing remains a critical
issue for modern healthcare systems.
Opinion Report
Defensive medicine has become a major
driver of laboratory activity and healthcare eco-
nomics, wherein many and seldom expensive
tests are requested against evidence-based
practice or violating well established criteria of
appropriateness, thus leading to the so-called
over-testing syndrome.5-7 In a survey performed
on a random sample of physicians practicing
in six high risk specialties,8 Studdert and col-
leagues reported that 59% of physicians
ordered unnecessary diagnostic tests or proce-
dures due to defensive medicine. Another
recent survey of the Italian Agency for
Regional Healthcare Systems (Agenzia
Nazionale per i Servizi Sanitari Regionali; AGE-
NAS) based on over 1500 hospital physicians
revealed that 58% of them admitted to practice
defensive medicine and, even more important-
ly, as many as 93% of hospital physicians were
not considering of suspending or reducing this
practice.9 It is also noteworthy that laboratory
tests were ranged first among the various
diagnostic investigations requested for defen-
sive reasons.
As specifically regards the ED, many unnec-
essary laboratory tests are also ordered in this
healthcare setting, with unfavorable conse-
quences on laboratory and healthcare organi-
zation.10 Beside defensive medicine, several
additional reasons have been identified under-
neath the behavior of inappropriate laboratory
tests request, including the broad use of multi-
test profiles, the diffusion of organ- or disease-
specific test panels, the request of tests not
really necessary or redundant, obsolete tests
analyses and excessive reporting delays.11,12
A paradigmatic example of misuse of labora-
tory test ordering can be identified in the diag-
nostic approach to patient with chest pain.
Despite the current guidelines for manage-
ment of patients with unstable angina and non
ST-segment elevation myocardial infarction
(STEMI) recommend to use only cardiospecific
troponins for the identification of myocardial
injury,13,14 and it also has been clearly demon-
strated that the use of high-sensitivity cardiac
troponins in a patient presenting with chest
pain is accurate enough to rapidly rule-out or
rule-in AMI,15 many emergency physicians still
request a large number of creatine kinase
isoenzyme MB (CK-MB) tests in association
with troponin. According to this evidence, dif-
ferent institutions have eliminated CK-MB
from emergency panel tests in the past years.
Interestingly, Singh et al. reported that the
elimination of CK-MB from the diagnostic
panel for patients with suspected acute coro-
Correspondence: Giuseppe Lippi, Section of
Clinical Biochemistry, University of Verona, via
delle Menegone, 37134 Verona, Italy.
E-mail: giuseppe.lippi@univr.it; ulippi@tin.it 
Key words: Defensive medicine; Emergency med-
icine; Emergency department; Laboratory testing;
Diagnosis.
Received for publication: 12 October 2015.
Accepted for publication: 31 December 2015.
This work is licensed under a Creative Commons
Attribution 4.0 License (by-nc 4.0).
©Copyright M. Montagnana and G. Lippi, 2016
Licensee PAGEPress, Italy
Emergency Care Journal 2016; 12:5581
doi:10.4081/ecj.2016.5581
No
n c
om
me
rci
al 
us
 on
ly
[page 18]                                                       [Emergency Care Journal 2016; 12:5581]
nary syndrome (ACS) was associated with a
considerable drop of requests for this biomark-
er, from approximately 12,000 to 150 per year,
with no effect on the diagnostic accuracy.16 Le
and colleagues recently reported the results of
a real world experience at Brigham and
Women’s Hospital, Boston, MA, USA.17 All cases
with normal values of troponin T (TnT) and
increased concentration of CK-MB were
reviewed, but no discrepancy between values
led to impairment of the ACS diagnosis.
Conversely, the elimination of CK-MB from
routine ED test menu was associated with cost
savings of approximately $47,000. 
The introduction of thyroid analyses (i.e.,
thyroid-stimulating hormone; TSH) in the ED
test panels is another controversial issue. The
clinical utility may be somehow justified in
rare clinical conditions such as myxedema
coma and thyroid storm, which are potentially
lethal.18-20 Atrial fibrillation (AF), the most fre-
quently for of arrhythmia observed in ED, can
also be triggered by hyperthyroidism.21
However, the real need to perform urgent TSH
testing is highly questionable, and each cir-
cumstance should be accurately weighted
against the need of preventing unnecessary
costs. Buccelletti and colleagues21 carried out a
cross-sectional observational study, in which
TSH was measured in all patients admitted to
the ED for new-onset AF over a 30 months peri-
od. The results of the study showed that a clin-
ical model incorporating a history of previous
thyroid disease, stroke/transient ischemic
attack and hypertension was effective to iden-
tify the presence of hyperthyroidism with a
remarkably high (i.e., 0.93) sensitivity, thus
making TSH testing virtually meaningless.
Bellew and colleagues studied 1964 consecu-
tive patients receiving a final diagnosis of AF
in the ED.22 Decreased (i.e., <0.3 U/mL) and
enhanced (>5 U/mL) TSH values could only be
observed in 2 and 11% of patients, respectively,
thus confirming that TSH measurement may
not be cost-effective in the ED.22 More recently,
Giacomini and colleagues assessed the clinical
usefulness of TSH test requests performed in
patients admitted to ED,23 and also found that
elevated and decreased TSH values were only
present in 3 and 1.2% of the patients, respec-
tively. In only one patient displaying an
increased TSH value the measurement of this
biomarker led to a substantial change of the
clinical decision making due to the presence of
Hashimoto thyroiditis. 
Despite the diagnostic value of lipase is
higher than that of amylase, the concomitant
request of both biomarkers is still common-
place in the ED for the diagnosis of acute pan-
creatitis.24 Nevertheless, it has been demon-
strated that the urgent, simultaneous assess-
ment of both amylase and lipase does not sig-
nificantly modify the accuracy of the
diagnosis.25-27 Indeed, the foremost limitation
of amylase is represented by the low specificity
for diagnosing pancreatitis, since increased
values are observed in a kaleidoscope of dis-
eases affecting the biliary tract, liver, intes-
tines, genitourinary tract, lungs, breast,
prostate, central nervous system and salivary
glands. Moreover, the diagnostic sensitivity of
amylase was also found to be lower than that of
lipase,28 wherein normal values of serum amy-
lase can be present in as many as 30% of
patients with acute alcoholic pancreatitis.29 It
is also noteworthy that lipase values persist
elevated for a long time after pancreatitis,
whereas amylase tends to normalize very rap-
idly, thus lowering its diagnostic sensitivity. As
for CK-MK, it has hence been concluded that
amylase testing does not provide add value
over lipase for initial assessment of patients
with suspected pancreatitis in the ED.30
Conclusions
Squeezed between lower economical
resources, increased volumes of testing and
enhanced healthcare expectations, clinical lab-
oratories are now facing a dedicate balance
between efficiency and efficacy.31 Recent sta-
tistics attests that defensive medicine con-
sumes 23 to 67% of laboratory resources, so
that this form of inappropriateness ends up to
magnify an already delicate equilibrium.32
Although the (unfavorable) clinical implica-
tions arising from defensive (emergency)
medicine will be further discussed in another
article published in this Journal, its negative
impact on the organization of clinical laborato-
ries is undeniable (Table 1), especially if one
considers the high volume of urgent testing
                             Opinion Report
Table 1. Negative impact of defensive (emergency) medicine on the organization clinical
laboratories.
No.                 Negative impact
1                          Incremental costs
2                          Derangement of laboratory organization
3                          Enhanced complexity of data management process
4                          Diagnostic delay attributable to performance of unnecessary testing
5                          Controversies and risk of false positive results
Figure 1. Organizational solutions for stat testing in clinical laboratories. a) Physical sep-
aration between routine and urgent testing; b) consolidation of routine and urgent test-
ing; c) urgent testing performed with point of care (POC) instrumentation and routine
testing carried out in the laboratory.
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currently carried out in clinical laboratories. As
such, educative or even regulatory interven-
tions are urgently needed to address problems
in the current liability system in order to
decrease the detrimental effects of defensive
(emergency) medicine in the laboratory.33
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